249 related articles for article (PubMed ID: 16761012)
1. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
[TBL] [Abstract][Full Text] [Related]
2. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
3. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
4. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Bella AJ; Brant WO; Lue TF; Brock GB
Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
Kim NN
Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
[TBL] [Abstract][Full Text] [Related]
6. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Schiefer J; Sparing R
Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
[TBL] [Abstract][Full Text] [Related]
7. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Küthe A; Montorsi F; Andersson KE; Stief CG
Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
[TBL] [Abstract][Full Text] [Related]
10. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
Aliaev IuG; Vinarov AZ; Akhvlediani ND
Urologiia; 2007; (1):45-6, 49. PubMed ID: 17471999
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects.
Werkström V; Svensson A; Andersson KE; Hedlund P
BJU Int; 2006 Aug; 98(2):414-23. PubMed ID: 16626307
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
de Tejada IS
Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
[TBL] [Abstract][Full Text] [Related]
16. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
18. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Carter JE
J Neurol Sci; 2007 Nov; 262(1-2):89-97. PubMed ID: 17706972
[TBL] [Abstract][Full Text] [Related]
19. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo.
Stief CG; Uckert S; Becker AJ; Truss MC; Jonas U
J Urol; 1998 Apr; 159(4):1390-3. PubMed ID: 9507890
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of erectile dysfunction in man.
Cirino G; Fusco F; Imbimbo C; Mirone V
Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
